WebJul 8, 2024 · Press Releases Date News Mar. 14, 2024 Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market Mar. 10, 2024 WebApr 15, 2024 · Sunshine Biopharma peers beat Sunshine Biopharma on 6 of the 10 factors compared. Sunshine Biopharma Company Profile . Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional …
Insider Buying: Sunshine Biopharma Inc. (NASDAQ: SBFM) Chief …
WebFeb 4, 2024 · Sunshine Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024. CI. 04/28. SUNE BIOP : Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market - Form 8-K. WebSunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization … new yorker style cartoon
Pharmaceutical Company Sunshine Biopharma
WebApr 17, 2024 · Sunshine Biopharma is developing novel Topoisomerase II inhibiting cancer therapies and PLpro inhibiting antiviral drugs. The Company has a strong IP backing, although much of it is tied in... WebApr 28, 2024 · Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market. MONTREAL, April 28, 2024 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization … WebDec 31, 2024 · On February 7, 2024, Sunshine Biopharma, Inc. (the "Company") received a duly executed research agreement (the "Research Agreement") with Sir Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Canada ("JGH") in connection with the Company's Adva-27a anticancer compound. new yorkers were shocked in